Navigation Links
Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that data from an ongoing Phase 1-2 clinical trial of its novel androgen receptor antagonist, MDV3100, will be presented in an oral presentation at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Session title: New Targeted Strategies for Patients with Prostate Cancer

Session date and time: Monday, June 2 at 11:30 a.m. Central Time

Abstract title: "Phase 1-2 Study of MDV3100 in Patients with Progressive

Castration-Resistant Prostate Cancer (CRPC)" (Abstract #5006)

To be presented by: Howard Scher, M.D., chief of the Genitourinary

Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at

Memorial Sloan-Kettering Cancer Center in New York, at approximately 12:15

p.m. Central Time

Location: W375e

Dr. Scher's presentation will include data appearing in the abstract posted today on the ASCO website, as well as additional study data not reflected in the abstract.

Medivation's ongoing Phase 1-2 trial of MDV3100 is an open-label dose-escalation study enrolling prostate cancer patients who have failed standard hormonal therapies. The study endpoints include safety, tolerability, pharmacokinetics, effects on serum PSA levels and disease progression. Medivation expects to complete the study and report final top-line results in 2008.

About Prostate Cancer

Prostate cancer is the most common type of cancer, other than skin cancer, and the second leading cause of cancer death in American men. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 200
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... 12, 2011 If you could learn that you have a ... and 75 percent of that chance could be altered by lifestyle ... of the nation,s leading online direct-to-consumer online lab test and health ... Your Number HealthScore as seen on The Biggest Loser ...
... 2011 Urologists for Patient Access to Care (UPAC) ... men should no longer receive prostate-specific antigen (PSA) blood ... major retrenchment in preventive health care." Dr. ... health care advocates to speak out to preserve prostate ...
Cached Medicine Technology:PersonaLabs and BioSignia Join to Offer Targeted Risk Assessment 2Cancer Detection Tool Saves Lives 2
(Date:8/22/2014)... (PRWEB) August 22, 2014 Japantown Dental ... a new teeth whitening technique. Air polishing is a ... appointments. , Dark teeth can be caused by a ... external stains and internal stains. External stains include coffee, ... be caused by certain medications, such as tetracycline, and ...
(Date:8/22/2014)... Princeton, Indiana (PRWEB) August 22, 2014 ... because Toyota Indiana is on the grow ... add 300 jobs by summer 2016 to boost production ... expansion will bring Toyota Indiana’s overall investment to $4 ... in North America while providing additional flexibility to adjust ...
(Date:8/22/2014)... LSU Health New Orleans School of Nursing was ... to increase access to advanced nursing education and ... as well as veterans. The Health Resources and ... and Human Services awarded the two-year grant. Scharalda ... project director., The Advanced Education Nursing Traineeship (AENT) ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
Breaking Medicine News(10 mins):Health News:Japantown Dental Introduces Air Polishing 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Millennium Treatment Group Has a New Website 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... 20 A team of medical,professionals from the ... services in Germany impressive. The NRH team has ... the US Army,s Europe Regional,Medical Command (ERMC) in ... and capability of our military health care system ...
... life of adolescents who think they are too fat ... This was a result of the all Germany Health ... of the Robert Koch Institute, as presented by Brbel-Maria ... Deutsches rzteblatt International (Dtsch Arztebl Int 2008, ...
... Symmetry Medical Inc.,(NYSE: SMA ), a leading ... and other medical markets, announced today that,it will release ... 2008 before the market opens on Tuesday, June 24, ... 8:00 a.m. ET on,Tuesday, June 24., A live ...
... 20 Women in Ireland will,soon be able ... by,Quest Diagnostics Incorporated (NYSE: DGX ), the ... with the Irish,National Cancer Screening Service (NCSS), Quest ... medical outcomes and,reduce anxiety wait time for women ...
... Hearing, TORONTO, June 20 /PRNewswire-FirstCall/ - Predictive ... announced the successful completion,of its agreement with one ... result of the completion of this project, PreMD ... for further product development and,other skin testing initiatives., ...
... Put Millions at Risk, SAN FRANCISCO, June 20 ... theft epidemic by making it easy for,people with access ... using,stolen information. Hospital workers, lab technicians and even janitors,with ... able to manipulate,the automated systems used by such industry ...
Cached Medicine News:Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 2Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 4Health News:'Feeling fat' is worse than being it 2Health News:Symmetry Medical to Report First Quarter 2008 Financial Results on June 24, 2008 2Health News:Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screening Program 2Health News:Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screening Program 3Health News:Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screening Program 4Health News:PreMD Successfully Completes Project for Health & Beauty Company 2Health News:Credit Card Companies Fueling Healthcare Associated Identity Theft (HAIT) Crimes 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Designed for peeling delicate epiretinal membrane in cases of premacular fibroplasia. Positive action closure. Barrel design with straight 20 gauge 40 gauge long shaft. 1 x 1.5 mm lightly serrated ja...
Triangular shaped tips. Marked for 5 mm and 10 mm tucks. Round knurled handle with polished finish....
Angled shafts with 9 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Left....
Medicine Products: